1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- Author
-
Sonya Youngju Park, Katherine Zukotynski, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Kalpna Prasad, Corina Millo, Erik Mittra, Nadine Mallak, and Don Wilson
- Subjects
Oncology ,medicine.medical_specialty ,Peptide receptor ,Clinical Sciences ,68Ga-DOTANOC ,somatostatin ,Ga-68-DOTATATE ,Internal medicine ,Receptors ,Medicine ,Radiology, Nuclear Medicine and imaging ,Receptors, Somatostatin ,Precision Medicine ,SSTR ,Cancer ,peptide receptor radionuclide therapy ,screening and diagnosis ,neuroendocrine neoplasms ,business.industry ,Somatostatin receptor ,Neurosciences ,Planar scintigraphy ,Pet imaging ,68Ga-DOTATATE ,Review article ,Neuroendocrine Tumors ,Detection ,Ga-68-DOTANOC ,Nuclear Medicine & Medical Imaging ,Somatostatin ,Good Health and Well Being ,Current practice ,Positron-Emission Tomography ,Radionuclide therapy ,Biomedical Imaging ,peptide receptor radionuclide ther-apy ,business ,The State of the Art ,4.2 Evaluation of markers and technologies - Abstract
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based γ-scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy-based Krenning score for PRRT eligibility. Also, to date, the role of SSTR PET in response assessment and predicting outcome remains under evaluation. In this comprehensive review article, we discuss the current role of SSTR PET in all aspects of neuroendocrine neoplasms, including its relation to conventional imaging, selection of patients for PRRT, and the current understanding of SSTR PET-based response assessment. We also provide a standardized reporting template for SSTR PET with a brief discussion.
- Published
- 2021